A Clinical Study of Cizutamig in Thyroid Eye Disease
ConditionThyroid Eye Disease, TED
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorCandid Therapeutics
About this trial
The purpose of this study is to evaluate the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of cizutamig in patients with thyroid eye disease (TED).
Eligibility criteria
Qualifiers
18-75 years old at the time of signing the Informed Consent Form
Diagnosis of Graves' Disease with active, moderate to severe TED in accordance with the Chinese Guidelines for the Diagnosis and Treatment of Thyroid-Associated Ophthalmology (2022) at Screening and Day 1
Disqualifiers
Inadequate clinical laboratory parameters at Screening
Active infection present
Receipt of, or inability to discontinue, any of the excluded therapies
History of progressive multifocal leukoencephalopathy
Trial design
Treatments tested in this trial
- Cizutamig will be dosed according to the protocol.
Treatment groups
38 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov